View ValuationMacro Group Pharmaceuticals (Macro Capital)E 将来の成長Future 基準チェック /06現在、 Macro Group Pharmaceuticals (Macro Capital)Eの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長13.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 02Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Mar 29, 2026Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Mar 29, 2026, at 15:00 Egypt Standard Time. Location: cairo EgyptBoard Change • May 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 21Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Apr 14, 2025Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Apr 14, 2025, at 15:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • Nov 15Third quarter 2024 earnings released: EPS: ج.م0.04 (vs ج.م0.12 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.04 (down from ج.م0.12 in 3Q 2023). Revenue: ج.م164.0m (down 35% from 3Q 2023). Net income: ج.م22.7m (down 67% from 3Q 2023). Profit margin: 14% (down from 27% in 3Q 2023). The decrease in margin was driven by lower revenue.Reported Earnings • Sep 07Second quarter 2024 earnings released: ج.م0.02 loss per share (vs ج.م0.03 profit in 2Q 2023)Second quarter 2024 results: ج.م0.02 loss per share (down from ج.م0.03 profit in 2Q 2023). Revenue: ج.م95.7m (down 47% from 2Q 2023). Net loss: ج.م10.7m (down 154% from profit in 2Q 2023).Reported Earnings • Apr 20Full year 2023 earnings released: ج.م0.48 loss per share (vs ج.م0.30 profit in FY 2022)Full year 2023 results: ج.م0.48 loss per share (down from ج.م0.30 profit in FY 2022). Revenue: ج.م526.0m (down 28% from FY 2022). Net loss: ج.م272.7m (down 257% from profit in FY 2022).Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ج.م2.47, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 24x in the Personal Products industry globally. Total loss to shareholders of 25% over the past year.Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ج.م3.57, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 25x in the Personal Products industry globally. Total returns to shareholders of 10% over the past year.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ج.م3.20, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 27x in the Personal Products industry globally. Total loss to shareholders of 14% over the past year.Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ج.م0.12 (vs ج.م0.10 in 3Q 2022)Third quarter 2023 results: EPS: ج.م0.12 (up from ج.م0.10 in 3Q 2022). Revenue: ج.م252.3m (up 17% from 3Q 2022). Net income: ج.م68.8m (up 18% from 3Q 2022). Profit margin: 27% (in line with 3Q 2022).Upcoming Dividend • Apr 11Upcoming dividend of ج.م0.11 per share at 2.0% yieldEligible shareholders must have bought the stock before 18 April 2023. Payment date: 31 October 2023. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Higher than average of industry peers (1.7%).Reported Earnings • Mar 07Full year 2022 earnings released: EPS: ج.م0.30 (vs ج.م0.26 in FY 2021)Full year 2022 results: EPS: ج.م0.30 (up from ج.م0.26 in FY 2021). Revenue: ج.م729.6m (up 23% from FY 2021). Net income: ج.م173.8m (up 18% from FY 2021). Profit margin: 24% (down from 25% in FY 2021). The decrease in margin was driven by higher expenses.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 21Second quarter 2022 earnings releasedSecond quarter 2022 results: EPS: ج.م0.071. Net income: ج.م40.7m (up ج.م40.7m from 2Q 2021). Over the next year, revenue is forecast to grow 27%, compared to a 9.1% growth forecast for the Personal Products industry in Egypt.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ج.م3.19, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Personal Products industry globally. Simply Wall St's valuation model estimates the intrinsic value at ج.م5.21 per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Macro Group Pharmaceuticals (Macro Capital)E は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CASE:MCRO - アナリストの将来予測と過去の財務データ ( )EGP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025895116119161N/A9/30/20258791325122N/A6/30/2025776120-913N/A3/31/202564562-23-2N/A12/31/2024520-38-87-74N/A9/30/2024256-437-2037N/A6/30/2024344-391-65-62N/A3/31/2024430-3603843N/A12/31/2023526-273-44-38N/A9/30/2023799142-54N/A6/30/20237621327282N/A3/31/2023750153-14-5N/A12/31/2022730174126135N/A9/30/20226971718794N/A6/30/20226661798695N/A3/31/20226111677380N/A12/31/20215941484450N/A9/30/2021544143-14-6N/A12/31/20204311353946N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MCROの予測収益成長が 貯蓄率 ( 15.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MCROの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MCROの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MCROの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MCROの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MCROの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 11:39終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Macro Group Pharmaceuticals (Macro Capital) S.A.E 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ahmed MoatazEFG-Hermes Research
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 02Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Mar 29, 2026Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Mar 29, 2026, at 15:00 Egypt Standard Time. Location: cairo Egypt
Board Change • May 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 21Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Apr 14, 2025Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Apr 14, 2025, at 15:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: ج.م0.04 (vs ج.م0.12 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.04 (down from ج.م0.12 in 3Q 2023). Revenue: ج.م164.0m (down 35% from 3Q 2023). Net income: ج.م22.7m (down 67% from 3Q 2023). Profit margin: 14% (down from 27% in 3Q 2023). The decrease in margin was driven by lower revenue.
Reported Earnings • Sep 07Second quarter 2024 earnings released: ج.م0.02 loss per share (vs ج.م0.03 profit in 2Q 2023)Second quarter 2024 results: ج.م0.02 loss per share (down from ج.م0.03 profit in 2Q 2023). Revenue: ج.م95.7m (down 47% from 2Q 2023). Net loss: ج.م10.7m (down 154% from profit in 2Q 2023).
Reported Earnings • Apr 20Full year 2023 earnings released: ج.م0.48 loss per share (vs ج.م0.30 profit in FY 2022)Full year 2023 results: ج.م0.48 loss per share (down from ج.م0.30 profit in FY 2022). Revenue: ج.م526.0m (down 28% from FY 2022). Net loss: ج.م272.7m (down 257% from profit in FY 2022).
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ج.م2.47, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 24x in the Personal Products industry globally. Total loss to shareholders of 25% over the past year.
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ج.م3.57, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 25x in the Personal Products industry globally. Total returns to shareholders of 10% over the past year.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ج.م3.20, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 27x in the Personal Products industry globally. Total loss to shareholders of 14% over the past year.
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ج.م0.12 (vs ج.م0.10 in 3Q 2022)Third quarter 2023 results: EPS: ج.م0.12 (up from ج.م0.10 in 3Q 2022). Revenue: ج.م252.3m (up 17% from 3Q 2022). Net income: ج.م68.8m (up 18% from 3Q 2022). Profit margin: 27% (in line with 3Q 2022).
Upcoming Dividend • Apr 11Upcoming dividend of ج.م0.11 per share at 2.0% yieldEligible shareholders must have bought the stock before 18 April 2023. Payment date: 31 October 2023. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Higher than average of industry peers (1.7%).
Reported Earnings • Mar 07Full year 2022 earnings released: EPS: ج.م0.30 (vs ج.م0.26 in FY 2021)Full year 2022 results: EPS: ج.م0.30 (up from ج.م0.26 in FY 2021). Revenue: ج.م729.6m (up 23% from FY 2021). Net income: ج.م173.8m (up 18% from FY 2021). Profit margin: 24% (down from 25% in FY 2021). The decrease in margin was driven by higher expenses.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 21Second quarter 2022 earnings releasedSecond quarter 2022 results: EPS: ج.م0.071. Net income: ج.م40.7m (up ج.م40.7m from 2Q 2021). Over the next year, revenue is forecast to grow 27%, compared to a 9.1% growth forecast for the Personal Products industry in Egypt.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ج.م3.19, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Personal Products industry globally. Simply Wall St's valuation model estimates the intrinsic value at ج.م5.21 per share.